Malcolm Ranson
Impact in
- Oncology top 0.2%
- Lung Cancer Research Studies
- HER2/EGFR in Cancer Research
- Cancer Cells and Metastasis
- Colorectal Cancer Treatments and Studies
- Pulmonary and Respiratory Medicine top 0.2%
- Lung Cancer Treatments and Mutations
Papers in
- Oncology 66
- Lung Cancer Research Studies 20
- Cancer Treatment and Pharmacology 13
- HER2/EGFR in Cancer Research 11
- Colorectal Cancer Treatments and Studies 10
-
- Lung Cancer Treatments and Mutations 35
- Co-authors
- Caroline Dive (35 shared papers)Fiona Helen Blackhall (15 shared papers)Andrew M. Hughes (17 shared papers)Alastair Greystoke (21 shared papers)Tim H. Ward (12 shared papers)Helen Swaisland (8 shared papers)Sarah J. Danson (15 shared papers)Matthew Krebs (5 shared papers)
- Journals
- British Journal of Cancer (21 papers)Annals of Oncology (15 papers)European Journal of Cancer (12 papers)Journal of Clinical Oncology (12 papers)Clinical Cancer Research (7 papers)
- Partner nations
- United KingdomUnited StatesNetherlands
In The Last Decade
Malcolm Ranson
153 papers receiving 13.9k citations
Malcolm Ranson's Hit Papers
Peers
Comparison fields: 5 of 137
- Oncology 6.8k
- Pulmonary and Respiratory Medicine 5.6k
- Cancer Research 2.4k
- Molecular Biology 5.0k
- Genetics 610
Countries citing papers authored by Malcolm Ranson
This map shows the geographic impact of Malcolm Ranson's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Malcolm Ranson with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Malcolm Ranson more than expected).
Fields of papers citing papers by Malcolm Ranson
This network shows the impact of papers produced by Malcolm Ranson. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Malcolm Ranson. The network helps show where Malcolm Ranson may publish in the future.
Co-authors
The 25 scholars most cited alongside Malcolm Ranson, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.
All Works
Showing the 20 most-cited of 160 papers — load more, or switch the sort, to bring in the rest.
| # | Work | ||
|---|---|---|---|
| 1 | AZD9291, an Irreversible EGFR TKI, Overcomes T790M-Mediated Resistance to EGFR Inhibitors in Lung Cancer Hit paper breakdown → | 2014 | 1867 |
| 2 | AZD9291 in EGFR Inhibitor–Resistant Non–Small-Cell Lung Cancer Hit paper breakdown → | 2015 | 1807 |
| 3 | Evaluation and Prognostic Significance of Circulating Tumor Cells in Patients With Non–Small-Cell Lung Cancer Hit paper breakdown → | 2011 | 766 |
| 4 | Phase I Safety, Pharmacokinetic, and Pharmacodynamic Trial of ZD1839, a Selective Oral Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor, in Patients With Five Selected Solid Tumor Types Hit paper breakdown → | 2002 | 732 |
| 5 | ZD1839, a Selective Oral Epidermal Growth Factor Receptor–Tyrosine Kinase Inhibitor, Is Well Tolerated and Active in Patients With Solid, Malignant Tumors: Results of a Phase I Trial Hit paper breakdown → | 2002 | 689 |
| 6 | Phase II Study of Single-Agent Navitoclax (ABT-263) and Biomarker Correlates in Patients with Relapsed Small Cell Lung Cancer Hit paper breakdown → | 2012 | 483 |
| 7 | 2011 | 407 | |
| 8 | 2011 | 366 | |
| 9 | 2004 | 329 | |
| 10 | 1997 | 267 | |
| 11 | 2010 | 260 | |
| 12 | 2000 | 247 | |
| 13 | 2002 | 223 | |
| 14 | 2007 | 220 | |
| 15 | 2009 | 205 | |
| 16 | 2001 | 197 | |
| 17 | 2009 | 195 | |
| 18 | 2010 | 176 | |
| 19 | 2004 | 168 | |
| 20 | 2011 | 140 |
About Malcolm Ranson
Malcolm Ranson is a scholar working on Oncology, Pulmonary and Respiratory Medicine, Molecular Biology, Pathology and Forensic Medicine and Cancer Research, having authored 160 papers that have together received 14.5k indexed citations. Recurring topics across this work include Lung Cancer Treatments and Mutations (35 papers), Lung Cancer Research Studies (20 papers), Cancer therapeutics and mechanisms (15 papers), Cancer Treatment and Pharmacology (13 papers), Cell death mechanisms and regulation (13 papers), HER2/EGFR in Cancer Research (11 papers), Cancer Genomics and Diagnostics (10 papers) and Colorectal Cancer Treatments and Studies (10 papers). The work is most often cited by research in Oncology (6.8k citations), Pulmonary and Respiratory Medicine (5.6k citations), Cancer Research (2.4k citations), Molecular Biology (5.0k citations) and Genetics (610 citations). Malcolm Ranson has collaborated with scholars based in United Kingdom, United States and Netherlands. Frequent co-authors include Caroline Dive, Fiona Helen Blackhall, Andrew M. Hughes, Alastair Greystoke, Tim H. Ward, Helen Swaisland, Sarah J. Danson, Matthew Krebs, Glen Clack and Lynsey J.C. Priest. Their work appears in journals such as British Journal of Cancer, Annals of Oncology, European Journal of Cancer, Journal of Clinical Oncology and Clinical Cancer Research.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.